NUVB Stock Summary and Trading Ideas (Nuvation Bio Class A | NYSE:NUVB)

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.

As of March 27, 2026, NUVB stock price declined to $4.25 with 3,980,854 million shares trading.

NUVB has a beta of 1.82, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.09 to the broad based SPY ETF.

NUVB has a market cap of $1.45 billion. This is considered a Small Cap stock.

Last quarter Nuvation Bio Class A reported $42 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.04.

In the last 3 years, NUVB traded as high as $9.75 and as low as $.95.

The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

NUVB has outperformed the market in the last year with a return of +127.3%, while the SPY ETF gained +13.1%. However, in the most recent history, NUVB shares have underperformed the stock market with its stock returning -54.8% in the last 3 month period and -4.3% for the last 2 week period, while SPY has returned -7.9% and -4.0%, respectively.

NUVB support price is $4.21 and resistance is $4.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.